Full-Time
Lead AI Tech Product Manager
GoodRx
1,001-5,000 employees
Prescription price comparison and coupons
Compensation Overview
$135k - $288k/yr
San Francisco, CA, USA
In Person
Bachelor's
 Product (1) |
|---|
Get referred to GoodRx
See people who can refer or advise you
- 8+ years of related product management experience, including 3+ years shipping AI, machine learning, or generative AI products in production.
- Experience thinking through the full arc of customer experience, from user needs and journey design through user evaluations and behavioral measurement, and using those insights to shape AI product decisions.
- Ability to lead AI platforms and cross-functional AI agents and products spanning platform capabilities and end-user experiences.
- Strong technical fluency in large language models, retrieval-augmented generation, agents, application programming interfaces, model evaluation, and machine learning operations concepts, with the ability to engage credibly with engineers and architects and translate technical considerations into product decisions.
- Track record of leading complex, cross-functional products in a matrixed organization, including guiding other product managers and influencing senior stakeholders without direct authority.
- Experience defining and instrumenting metrics for AI product quality, adoption, and business impact.
- Demonstrated ability to navigate complex and ambiguous product problems, breaking them into actionable solutions while balancing technical, customer, and business considerations.
- Bachelor's degree in a technical field or equivalent experience.
- Own the product vision, strategy, roadmap, and delivery for one or more AI use-case pods, balancing technical constraints, customer needs, and business objectives.
- Translate business objectives and customer needs into detailed, technically complex product requirements for large-language-model-based systems, agents, and evaluation pipelines; make build, buy, or partner recommendations and navigate trade-offs across technical feasibility, customer value, and business impact.
- Drive execution across engineering, data science, design, legal, and compliance; unblock teams, manage cross-functional dependencies, drive alignment and decision-making, and manage stakeholder communication up to the executive level.
- Define success metrics and evaluation criteria for AI features; partner with the center of excellence evaluation function to ensure quality, safety, and regulatory readiness before launch, and use performance data and customer feedback to inform ongoing product decisions and roadmap priorities.
- Shepherd initiatives through AI governance review, ensuring speed with appropriate guardrails while balancing technical, user, business, and regulatory considerations.
- Set product standards and playbooks for the center of excellence, mentor pod product managers, and raise the bar on AI product craft across GoodRx.
- Healthcare, pharmaceutical, finance, or other regulated-industry experience.
- Familiarity with AI governance frameworks such as the NIST AI Risk Management Framework and EU AI Act, and responsible AI practices.
- Experience with agentic systems, Model Context Protocol, or AI evaluation tooling.
- An advanced degree.
GoodRx provides price comparisons, coupons, and discounts for prescription medications through its website and mobile app. It partners with pharmacies to offer savings at the point of sale, earning referral fees. It also offers GoodRx Gold subscription with deeper discounts and earns revenue from ads and partnerships. The goal is to save people money on prescriptions and improve access to affordable medicines.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Santa Monica, California
Founded
2005
Get referred to GoodRx
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $200.4 million; Pharma Direct rose 76%.
- Subscription revenue jumped 39% after Companion launched in May 2026.
- September 3, 2026 Companion Family Plan expands household memberships to dependents and pets.
What critics are saying
- Prescription transactions revenue fell 24% in Q1 2026, crushing the core marketplace.
- FTC's 2023 privacy order bans advertising data sharing and burdens compliance through 2026.
- If Pharma Direct slows, GoodRx loses its replacement engine and returns to stagnant coupon business.
What makes GoodRx unique
- GoodRx's pharmacy network spans nearly every U.S. pharmacy, backing nationwide price transparency.
- Companion bundles prescriptions, telehealth, dental, vision, labs, and imaging into one membership.
- Pharma Direct programs give GoodRx manufacturer-funded pricing leverage, especially for GLP-1 access.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical, dental, and vision insurance
401(k) with a company match
ESPP
Unlimited vacation
"Take care of yourself" days
11 paid holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%GoodRx expands subscription strategy with Companion Family Plan. New $24.99 monthly plan includes a primary member and up to four dependents, including children, adults, and pets, with more than 250 generic medications available for free and savings on dental, vision, lab and imaging services. September 3, 2026. 9:17 AM SANTA MONICA, Calif. - GoodRx today launched the Companion Family Plan, expanding its everyday healthcare subscription to entire households, including children, adult family members, and pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordable, predictably priced membership. "Families don't experience healthcare costs one person at a time. They're simultaneously managing prescriptions and care for kids, parents, partners, and even pets," said Wendy Barnes, President and CEO of GoodRx. "Expanding Companion across the entire household allows us to support consumers in a way that reflects this reality. It also advances our strategy to make GoodRx a more central part of how consumers navigate and pay for healthcare." One Plan. More Ways for Families to Save. The Companion Family Plan, which costs $24.99 per month or $16.99 per month when paying annually, extends Companion benefits to a primary member and up to four dependents, which may include children, adult family members, and pets. Members can access more than 250 eligible generic medications for free and hundreds more for under $10 at nearly every pharmacy nationwide, plus savings on dental, vision, lab and imaging services. The primary member also receives access to $19 online care visits. Together, these features give families an affordable and predictable way to save across prescriptions and common healthcare needs. Building a Broader Subscription Offering The Companion Family Plan expands the reach and value of GoodRx's subscription offering, creating a more continuous way to support consumers beyond individual prescription transactions. Building on more than a decade of medication pricing expertise, extensive relationships with retail pharmacies, and a trusted consumer brand, GoodRx is uniquely positioned to scale this model. Companion complements the company's condition-focused offerings for weight loss, erectile dysfunction, and hair loss. Supporting Growth and Retention for Retail Pharmacy Partners Companion gives members access to meaningfully lower prices than they would receive through a traditional prescription discount, while allowing them to continue filling at the pharmacies they already know and trust. This helps retail pharmacy partners strengthen patient relationships, support prescription volume, and deliver a more compelling consumer experience, with no additional cost to participate. The Companion Family Plan broadens those benefits while preserving favorable pharmacy economics and reinforcing the value of GoodRx's retail pharmacy network. Making Companion an Employee Benefit GoodRx plans to offer Companion through Employer Direct, giving employers a flexible, predictable way to subsidize memberships and help lower employees' out-of-pocket healthcare costs. Companion can complement existing health benefits by addressing prescription costs and other coverage gaps, or extend healthcare savings to workers who are not eligible for traditional benefits. The expansion creates a new channel for Companion while giving employers another way to support healthcare affordability for their workforce. Get the latest Chain Drug Review news delivered straight to your inbox. Have news to share? Send Chain Drug Review your press releases and announcements.
GoodRx (NASDAQ:GDRX) major shareholder sells $437,819.12 in stock. August 26, 2026 Key points. * Francisco Partners IV sold 127,273 GoodRx shares for $437,819 at an average price of $3.44, reducing its ownership by 16.51% to 643,466 shares. The shareholder also sold more than 2.6 million additional shares in transactions from August 19-26. * GoodRx shares rose 5.2% to $3.65, giving the company a market capitalization of approximately $1.25 billion. Its latest quarterly results matched earnings expectations at $0.08 per share and exceeded revenue estimates, although revenue declined 1.3% year over year. * Analyst sentiment remains mixed, with four Buy, six Hold and three Sell ratings and a consensus price target of $4.23. Recent target changes included UBS raising its target to $3.75 and Citigroup increasing its target to $5.00. * Interested in GoodRx? Here are five stocks we like better. GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $3.44, for a total value of $437,819.12. Following the completion of the transaction, the insider directly owned 643,466 shares of the company's stock, valued at approximately $2,213,523.04. This trade represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC. Francisco Partners Iv, L.P. also recently made the following trade(s): * On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. * On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total value of $496,835.24. * On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50. * On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68. * On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75. GoodRx stock up 5.2%. NASDAQ:GDRX traded up $0.18 during trading hours on Wednesday, reaching $3.65. The company had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60. The business's 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $2.66. Discover more Integrated Circuits Stock Screener Tool Financial Markets News GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.09 earnings per share. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year. Analyst ratings changes. A number of research firms recently weighed in on GDRX. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. UBS Group upped their target price on GoodRx from $2.50 to $3.75 and gave the stock a "neutral" rating in a research report on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Citigroup lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, GoodRx has an average rating of "Hold" and a consensus target price of $4.23. Institutional inflows and outflows. A number of large investors have recently modified their holdings of the stock. Lazard Asset Management LLC grew its holdings in GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after buying an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its stake in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company's stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its stake in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company's stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP purchased a new position in GoodRx during the 3rd quarter worth $33,000. Institutional investors own 63.77% of the company's stock. About GoodRx. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
GoodRx reported second-quarter revenues of $200.4 million, down 1.3% year-on-year but exceeding analyst expectations by 3.5%. The prescription drug price comparison platform delivered the slowest revenue growth among seven healthcare technology stocks tracked in the analysis. Despite the modest performance, GoodRx provided strong forward guidance. Its full-year revenue and EBITDA forecasts both topped analyst expectations. The stock has responded positively, rising 14.1% since the earnings announcement and currently trading at $3.73. The company, founded in 2011, helps consumers find lower prescription medication prices through comparison tools and discount codes. The healthcare technology sector as a group reported strong results, with revenues beating consensus estimates by 3.7% and next quarter guidance exceeding expectations by 2.8%. Share prices across the sector have risen 6.8% on average following the latest earnings.
GoodRx (NASDAQ:GDRX) stock price expected to rise, Citigroup Analyst says. August 11, 2026 Key points. * Citigroup raised GoodRx's price target from $4.00 to $5.00 and maintained a "buy" rating, implying 31.41% upside from the previous close. * Analyst sentiment remains mixed: GoodRx has an average "Hold" rating and a consensus price target of $4.16, while Wells Fargo and TD Cowen also raised their targets to $5.00. * GoodRx reported quarterly EPS of $0.08, in line with estimates, and revenue of $200.41 million, above expectations but down 1.3% year over year. The stock recently traded at $3.81, while institutional investors own 63.77% of shares. * MarketBeat previews the top five stocks to own by September 1st. GoodRx (NASDAQ:GDRX - Get Free Report) had its price target increased by analysts at Citigroup from $4.00 to $5.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's price objective indicates a potential upside of 31.41% from the company's previous close. A number of other analysts also recently weighed in on the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $4.00 price target on shares of GoodRx in a report on Friday. Wells Fargo & Company upped their target price on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research report on Friday. TD Cowen lifted their target price on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday. Leerink Partners set a $5.00 price target on GoodRx in a report on Thursday. Finally, Weiss Ratings upgraded shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, GoodRx currently has an average rating of "Hold" and an average price target of $4.16. GoodRx price performance. GDRX stock traded up $0.14 during midday trading on Tuesday, reaching $3.81. 1,750,660 shares of the stock were exchanged, compared to its average volume of 2,112,026. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The company has a fifty day moving average price of $2.96 and a 200 day moving average price of $2.55. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a market capitalization of $1.30 billion, a PE ratio of 95.15, a P/E/G ratio of 1.70 and a beta of 1.60. GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same period last year, the company earned $0.09 earnings per share. The business's quarterly revenue was down 1.3% on a year-over-year basis. As a group, analysts expect that GoodRx will post 0.17 EPS for the current fiscal year. Institutional inflows and outflows. A number of large investors have recently made changes to their positions in the business. Prescott Group Capital Management L.L.C. bought a new stake in shares of GoodRx during the fourth quarter worth about $4,812,000. Technology Crossover Management X Ltd. acquired a new position in GoodRx during the 2nd quarter valued at about $4,762,000. Northwestern Mutual Wealth Management Co. boosted its stake in GoodRx by 10,242.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company's stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. AQR Capital Management LLC increased its holdings in GoodRx by 188.0% during the 4th quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company's stock worth $3,140,000 after purchasing an additional 756,209 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares in the last quarter. 63.77% of the stock is owned by institutional investors. GoodRx company profile. GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
GoodRx is expanding beyond prescription savings as subscription revenue climbed 39% year over year. CEO Wendy Barnes told Yahoo Finance the company expects to return to top-line growth this year, earlier than anticipated, though at low single-digit rates. The platform maintains around 280 million site visits but is seeing shifts in user behaviour. There's been considerable increase in users seeking GLP-1 coverage as many employers don't cover these medications. Barnes said users are looking for longer-term value and the ability to fill their entire medicine cabinet rather than using multiple point solutions. Direct-to-pharma sales rose 76% year over year.